Publications by authors named "Catherine Nalpas"
Background: An unmet need exists for effective antivirals to treat patients hospitalized with influenza. The results of 2 Phase 3 studies evaluating the efficacy and safety of pimodivir in combination with investigator-chosen standard-of-care (SoC) treatment are presented.
Methods: Hospitalized patients (hospital study; NCT03376321) and high-risk outpatients (outpatient study; NCT03381196) with laboratory-confirmed influenza A infection were randomized 1:1 to 600 mg pimodivir twice daily (BID) + SoC, or placebo BID + SoC for 5 days.
Background: The urgent need in HCV-infected patients with liver disease mandated the rapid implementation of IFN-free DAA combination therapies following their regulatory approval in 2014 and 2015 without full knowledge of the optimal combinations and regimens. Investigating the evolution of the DAA utilization patterns and treatment outcomes could provide learnings for future situations.
Methods: This was an analysis of a prospective observational database from the German Hepatitis C Registry (DHC-R) covering a period from May 2014 to September 2015.
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
PLoS One
August 2017
Article Synopsis
- HCV GT4 accounts for around 20% of global hepatitis C cases, and the study evaluated the effectiveness and safety of simeprevir combined with PR in treatment-naïve patients for 12 weeks.
- 67 patients were assessed, and half qualified for the shorter 12-week treatment, showing a 97% sustained virologic response rate at 12 weeks after treatment.
- No new safety concerns were reported, and patients on the 12-week regimen experienced fewer severe side effects compared to those who continued treatment for 24 weeks.